Related Experiment Video
Updated: Sep 25, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Biological Dose Optimization for Particle Arc Therapy Using Helium and Carbon Ions
Stewart Mein1, Thomas Tessonnier2, Benedikt Kopp1
1Clinical Cooperation Unit Translational Radiation Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital (UKHD) and German Cancer Research Center (DKFZ), Heidelberg, Germany; Division of Molecular and Translational Radiation Oncology, Department of Radiation Oncology, Heidelberg Faculty of Medicine (MFHD) and Heidelberg University Hospital (UKHD), Heidelberg Ion-Beam Therapy Center (HIT), Heidelberg, Germany; German Cancer Consortium (DKTK) Core-Center Heidelberg, German Cancer Research Center (DKFZ), Heidelberg, Germany; Clinical Cooperation Unit Radiation Oncology, Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation Oncology (NCRO), Heidelberg University and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Spot-scanning hadron arc (SHArc) therapy optimizes particle arc therapy for helium and carbon ions, improving target dose and sparing normal tissues. This advanced technique shows promise for clinical translation in cancer treatment.
Area of Science:
- Medical Physics
- Radiation Oncology
- Particle Therapy
Background:
- Particle arc therapy offers potential advantages over conventional techniques.
- Helium and carbon ions are used in advanced radiation therapy.
- Optimizing dose delivery is crucial for treatment efficacy and safety.
Purpose of the Study:
- To present biological dose optimization for particle arc therapy using helium and carbon ions.
- To evaluate the Spot-Scanning Hadron Arc (SHArc) delivery technique.
- To compare SHArc with conventional treatment planning methods.
Main Methods:
- Developed SHArc optimization for spot-scanning delivery using RayStation and FRoG.
- Applied the algorithm to three patient cases (glioblastoma, prostate adenocarcinoma, skull-base chordoma).
- Evaluated biological dose and dose-averaged Linear Energy Transfer (LETd) against VMAT and 2-field intensity modulated particle therapy.
Main Results:
- SHArc met clinical planning goals for target coverage and OARs.
- Achieved substantial reductions in normal tissue dose (40%-70%) compared to VMAT.
- Increased target LETd significantly with carbon ions (from ~40-60 to ~80-140 keV/µm).
Conclusions:
- SHArc therapy offers benefits including increased normal tissue sparing and enhanced target LETd.
- Potential reduction of high-LET components in organs at risk was observed.
- Further development of SHArc treatment planning is warranted for clinical translation.
More Related Videos
07:57Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
Published on: March 24, 2022
06:20Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
Published on: March 11, 2021
Related Concept Videos
Biological Effects of Radiation
Radiation: Applications
The average...